JNM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH RSS TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lebtahi, R.
Right arrow Articles by Le Guludec, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lebtahi, R.
Right arrow Articles by Le Guludec, D.
Journal of Nuclear Medicine Vol. 43 No. 7 889-895
© 2002 by Society of Nuclear Medicine


Clinical Investigations

Detection of Neuroendocrine Tumors: 99mTc-P829 Scintigraphy Compared with 111In-Pentetreotide Scintigraphy

Rachida Lebtahi, MD, PhD1, Joseph Le Cloirec, MD2, Claire Houzard, MD3, Doumit Daou, MD1, Iradj Sobhani, MD, PhD4, Geneviève Sassolas, MD3, Michel Mignon, MD, PhD4, Patrick Bourguet, MD, PhD2 and Dominique Le Guludec, MD, PhD1

1 Nuclear Medicine Department, Hôpital Bichat, Assistance Publique-Hôpitaux de Paris, Paris, France
2 Nuclear Medicine Department, Centre Eugène Marquis, Rennes, France
3 Nuclear Medicine Department, Hôpital Universitaire Neuro-Cardiologique, Lyon, France
4 Gastroenterology Department, Hôpital Bichat, Assistance Publique-Hôpitaux de Paris, Paris, France

The aim of this study was to evaluate the diagnostic value of a new somatostatin analog, 99mTc-P829, compared with that of 111In-pentetreotide. Methods: Forty-three patients (32 men, 11 women; age range, 24–78 y; mean age, 56 y) with biologically or histologically proven neuroendocrine tumors were prospectively included: 11 patients with Zollinger-Ellison syndrome, 16 patients with carcinoid tumors, and 16 patients with other types of functioning (n = 6) or nonfunctioning (n = 10) endocrine tumors. 111In-Pentetreotide planar images (head, chest, abdomen, and pelvis) were obtained 4 and 24 h after injection of 10 µg somatostatin analog labeled with 148 ± 17 MBq 111In, and SPECT was performed 24 h after injection. Similar 99mTc-P829 planar images were obtained at 1, 4–6, and 24 h after injection of 50 µg peptide labeled with 991.6 ± 187.59 MBq 99mTc. Abdominal SPECT was performed 4–6 h after injection. Results: 111In-Pentetreotide detected 203 tumoral sites in 39 (91%) of 43 patients, whereas 99mTc-P829 detected 77 sites in 28 (65%) of 43 patients (P < 0.005). In the liver, 129 sites (in 24 patients) were detected by 111In-pentetreotide scintigraphy and 34 sites (in 10 patients) were detected by 99mTc-P829 scintigraphy. Conclusion: In patients with endocrine tumors, the detection rate of 99mTc-P829 scintigraphy was lower than that of 111In-pentetreotide scintigraphy, which appeared to be more sensitive, especially for liver metastases.

Key Words: somatostatin receptor scintigraphy • 99mTc-P829 scintigraphy • endocrine tumors




This article has been cited by other articles:


Home page
Endocr Relat CancerHome page
D. J Kwekkeboom, B. L Kam, M. van Essen, J. J M Teunissen, C. H J van Eijck, R. Valkema, M. de Jong, W. W de Herder, and E. P Krenning
Somatostatin receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors
Endocr. Relat. Cancer, January 29, 2010; 17(1): R53 - R73.
[Abstract] [Full Text] [PDF]


Home page
Endocr Relat CancerHome page
S Scigliano, R Lebtahi, F Maire, J L Stievenart, R Kianmanesh, A Sauvanet, M P Vullierme, A Couvelard, J Belghiti, P Ruszniewski, et al.
Clinical and imaging follow-up after exhaustive liver resection of endocrine metastases: a 15-year monocentric experience
Endocr. Relat. Cancer, September 1, 2009; 16(3): 977 - 990.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
M. Rodrigues, S. Li, M. Gabriel, D. Heute, M. Greifeneder, and I. Virgolini
99mTc-Depreotide Scintigraphy Versus 18F-FDG-PET in the Diagnosis of Radioiodine-Negative Thyroid Cancer
J. Clin. Endocrinol. Metab., October 1, 2006; 91(10): 3997 - 4000.
[Abstract] [Full Text] [PDF]


Home page
JNMHome page
D. Storch, M. Behe, M. A. Walter, J. Chen, P. Powell, R. Mikolajczak, and H. R. Macke
Evaluation of [99mTc/EDDA/HYNIC0]Octreotide Derivatives Compared with [111In-DOTA0,Tyr3, Thr8]Octreotide and [111In-DTPA0]Octreotide: Does Tumor or Pancreas Uptake Correlate with the Rate of Internalization?
J. Nucl. Med., September 1, 2005; 46(9): 1561 - 1569.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
M. Ginj, J. Chen, M. A. Walter, V. Eltschinger, J. C. Reubi, and H. R. Maecke
Preclinical Evaluation of New and Highly Potent Analogues of Octreotide for Predictive Imaging and Targeted Radiotherapy
Clin. Cancer Res., February 1, 2005; 11(3): 1136 - 1145.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
B. Van Den Bossche and C. Van de Wiele
Receptor Imaging in Oncology by Means of Nuclear Medicine: Current Status
J. Clin. Oncol., September 1, 2004; 22(17): 3593 - 3607.
[Abstract] [Full Text] [PDF]


Home page
Endocr. Rev.Home page
J. C. Reubi
Peptide Receptors as Molecular Targets for Cancer Diagnosis and Therapy
Endocr. Rev., August 1, 2003; 24(4): 389 - 427.
[Abstract] [Full Text] [PDF]


Home page
JNMHome page
M. Gabriel, C. Decristoforo, E. Donnemiller, H. Ulmer, C. Watfah Rychlinski, S. J. Mather, and R. Moncayo
An Intrapatient Comparison of 99mTc-EDDA/HYNIC-TOC with 111In-DTPA-Octreotide for Diagnosis of Somatostatin Receptor-Expressing Tumors
J. Nucl. Med., May 1, 2003; 44(5): 708 - 716.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH RSS TABLE OF CONTENTS
JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY THE JOURNAL OF NUCLEAR MEDICINE
Copyright © 2002 by the Society of Nuclear Medicine.